CapnoPharm is a commercially active company, generating revenue through both B2B and B2C channels. From 2015 to 2020, our sales have sustained a 15% yearly average increase. Then, CapnoPharm resisted well by remaining in profit during the Covid pandemic.

Please visit our investors page for investment opportunities and information on the biotech trends behind our business.